Report of the Indiana University School of Medicine Task Force on Establishing an Adult Stem Cell Research Center by Broxmeyer, H & Meslin, Eric M.
Report of the Indiana University
School of  Medicine Task Force
on Establishing an 
Adult Stem Cell Research Center
November 2005
Hal Broxmeyer, Ph.D.
Distinguished Professor
Chairman & Mary Margaret Walther
Professor of Microbiology/Immunology
Professor of Medicine
Scientiﬁc Director of the Walther Oncology Center
Eric M. Meslin, Ph.D.
Director, Indiana University Center for Bioethics 
Assistant Dean for Bioethics, IU School of Medicine 
Professor of Medicine, Medical & Molecular Genetics, 
and Philosophy
 
Acknowledgements 
 
Funding for this report was provided through an Appropriation to the Indiana University 
School of Medicine by the Indiana General Assembly. We would like to thank Brandon 
Brown who provided research assistance throughout our work on this report and was an 
invaluable resource; and Amy Hatfield, M.L.S. who designed and prepared the final 
version of the report. We would also like to thank the many IU investigators who made 
time available to meet with us and who offered helpful comments on a draft of this 
report. 
 
 
H.B. 
E.M.M. 
 
  1  
Executive Summary 
 
In June 2005 Indiana University  School of Medicine (IUSM) Dean D. Craig Brater, 
M.D., appointed Hal Broxmeyer, Ph.D., (Director, Walther Oncology Center) and Eric 
Meslin, Ph.D.  (Director, Indiana University Center for Bioethics) to co-chair a Task 
Force charged with assessing the feasibility of establishing an Adult Stem Cell Center at 
Indiana University. The origin of Dean Brater’s request was the passage of Indiana Bill, 
S-268, signed into law by Governor Mitch Daniels on May 20, 2005. The law affects the 
conduct of research involving human cloning, embryonic stem cells and adult stem cells, 
and includes a provision (Chapter 29.7.2) permitting the “the board of trustees of Indiana 
University [to] establish an adult stem cell research center”. The Dean’s establishment of 
the Task Force is intended to provide the first of what may be several assessments that 
will be needed to provide a full picture of the opportunities. 
 
The Task Force met with approximately 40 IUSM-affiliated investigators on eight 
separate occasions between July-September 2005, including a half-day retreat on 
September 29. This report, which is an outgrowth of those encounters, provides seven 
conclusions and seven recommendations that are provided below. Additional information 
is contained in four accompanying Appendices. 
 
Conclusions
 
1. The IU School of Medicine has a well-established and diverse base of stem cell 
investigators working in several areas. This suggests that the necessary foundation 
exists at IUSM on which to build a Center. [See Appendix 1] 
 
2. Many potential disease targets are being studied by IUSM investigators, involving 
seven different cell sources. Among these, three areas of prominent research focus have 
shown promising potential as therapeutic foci for adult stem cells: cancer and its many 
variants, cardiovascular disease, and neurodegenerative disorders.  
 
3. There is evidence of the capacity to obtain external support for stem cell research 
at IUSM. Over $23 million from public and private sources has been obtained by IUSM 
investigators who self-identified as working with adult stem cells.  
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4. There is evidence of positive clinical results from current research efforts and 
emerging clinical trials in other areas, including blood and bone marrow transplants, an 
FDA approval of a stem cell selection device based on work done at IUSM, and an FDA-
approved clinical trial involving endothelial progenitor cells used to stimulate angiogenic 
growth in deteriorating limbs. 
 
5. Many potential scientific benefits are likely to arise from establishing an Adult 
Stem Cell Center, including: attracting new investigators to IUSM and in so doing 
increase the likelihood of attracting additional external funding; ,enhancing synergistic 
collaboration, bringing multiple cell fields and sources into contact, and translating 
scientific work into clinical trials. This increased activity may, if successful, translate into 
additional intellectual property. 
 
6. There are several domestic and international initiatives that will have an impact 
on any IUSM (or state-wide) initiative, including state and federal legislation that 
provide funding for stem cell initiatives, and the recent announcements in other countries 
to build capacity. [See Appendix 2] 
 
7. There is growing agreement that advances in stem cell investigation are now 
being made with an eye to cooperative efforts in research, rather than competitive 
ones. Time is of the essence if Indiana and IUSM are to attract and retain quality 
researchers and promote leading contributions to knowledge about stem cells. 
 
Recommendations 
 
Recommendation 1. The IUSM should move forward expeditiously with plans to 
develop and establish an Adult Stem Cell Center.  If a Center is not established soon, 
much of the opportunity for Indiana to take a leading role in adult stem cell research may 
be lost. 
 
Recommendation 2. The Center should approach research from the perspective of both 
cell-type and disease target, building from those areas in which IUSM has already 
demonstrated progress: Hematopoiesis, Cardiovascular disease, and Cancer. 
 
Recommendation 3. The Center should promote research at all levels, from basic 
science through therapeutics. However, emphasis should be given to the promotion of 
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translational research, and should encourage and enable any application of stem cells for 
patient treatment and cure. 
 
Recommendation 4. The Center should have a multidisciplinary structure, involving 
basic science investigators, clinicians, imaging experts, and geneticists, among others. 
This would allow stem cell research to draw on many areas of science, medicine, and 
technology to ensure that all the potential therapeutic benefits of adult stem cells are 
realized. Take for example the involvement of radiologists and biological microscopists 
for imaging. It would be feasible and tactical to recruit additional researchers to capitalize 
on existing strengths in imaging who are capable of following the migration/insertion of 
labeled stem cells into the targeted organ in 3-D rendering, or following dynamic events 
in 4-D (time); and genomic analysts using RNA arrays as a particularly good way to look 
at global changes in gene expression during differentiation. 
 
Recommendation 5. The Center should work to address applications for stem cells 
in research on which IUSM, as yet, has not been able to focus. There are several 
examples of this, such as diabetes mellitus, recognized as a fast-growing and very 
important area of research. Also in this category are certain neurodegenerative disorders, 
among them, spinal cord injury, Parkinsonism, and auditory cell replacement. 
 
Recommendation 6. While describing the potential scientific and clinical merits of such 
a Center are necessary for moving forward with plans for its establishment, other 
logistical and financial issues must be addressed separately. The IUSM should seek 
additional input on the following issues: 
 
• Costs and sources of financing for both start-up and long-term support; 
 
• Logistics, including the space (whether virtual or concrete) in which a Center 
would be located; 
 
• Administrative structure, including whether the Center will function as its 
own department, be housed within an existing department or school, and other 
factors related to reporting relationships; 
 
• Organization of the Center, involving status of faculty (full or part time), and 
possible cross-appointments; and 
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• Operational focus, both initially and also as expansion and development 
occur. 
 
Recommendation 7. The IUSM should develop a database (or refine an existing one) 
that can identify investigators, publications, and grant support directly related to 
stem cell research. As the Task Force discovered, there are little data to accurately 
inventory investigators who are conducting stem cell research, how productive they are, 
or how much stem-cell specific support they are receiving. More accurate data will be 
invaluable in developing excellence in this area. 
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Personal Comments by the Co-Chairs 
 
One of the challenging features of our efforts to provide advice on the establishment of 
an Adult Stem Cell Center at the IU School of Medicine was the need to describe the 
opportunities and potential in a way that did not compromise the scientific freedom and 
integrity of IUSM scientists who wish to work on embryonic stem cells. For example, it 
is one thing to recommend that IUSM undertake the steps necessary to fully realize the 
potential of researchers working in (or planning to work in) the many areas of adult stem 
cell research—which we jointly and unequivocally do—it is another thing to make this 
recommendation knowing that some will interpret it as simultaneously recommending 
that adult stem cells and only adult stem cells can be studied in the proposed Center. The 
latter interpretation of our recommendations would be wrong. Since it is currently legal in 
the United States to use federal funds to support research on embryonic stem cells (under 
very specific conditions and limitations), we would be remiss if we were to recommend 
that an Adult Stem Cell Center at Indiana University be established that would prohibit 
what the White House, the NIH, the US Congress and Indiana law permit. Therefore, in 
making the recommendations contained in this report we wish to make clear that any 
progress towards establishing an Adult Stem Cell Center should be mindful of the risk 
that is manifest in unduly limiting the resources to scientists that only work on adult stem 
cells. Some investigators will also want to work with embryonic stem cells in addition to 
adult stem cells, or may only wish to work with embryonic stem cells, and as such may 
feel uncomfortable with or excluded from the resources of the Center. This could lead to 
problems in retention and/or recruitment of outstanding scientists. Given these 
considerations we personally feel strongly that every consideration be given to 
establishing an IU Stem Cell Research Center, without specifying (in name) the specific 
type of stem cells that will be studied therein. 
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REPORT OF THE INDIANA UNIVERSITY SCHOOL OF MEDICINE TASK 
FORCE ON ESTABLISHING AN 
ADULT STEM CELL RESEARCH CENTER 
 
A. History, Mandate, and Process of Adult Stem Cell Center Task Force 
 
Box A 
 
Indiana Senate Bill S-268 
 
Chapter 29.7 Adult Stem Cell Research Center 
 
Sec. 1 As used in this chapter, “center” refers to an 
adult stem cell research center established under 
section 2 of this chapter to carry out the duties 
specified by this chapter. 
Sec. 2 The board of trustees of Indiana University 
may establish an adult stem cell research center. 
Sec. 3 The center must be under the administration 
of the school of medicine 
Sec. 4 The dean of the school of medicine shall 
appoint the director of the center. 
Sec. 5 The board of trustees of Indiana University 
may receive, accept, hold, and apply donations, 
bequests of funds, property, gifts, and other 
income in support of the center’s purposes. 
Sec. 6 The center shall: 
(1) conduct a thorough and 
comprehensive needs assessment of 
the state of science of adult stem cell 
research; and  
(2) develop strategies to move Indiana 
University into the forefront of the 
nation in its capacity to attract and 
retain adult stem cell researchers. 
In June 2005, Indiana University School of Medicine (IUSM) Dean D. Craig Brater, 
M.D., appointed Hal Broxmeyer, Ph.D., (Chairman, Department of Microbiology and 
Immunology, and Scientific Director, Walther Oncology Center Director) and Eric 
Meslin, Ph.D. (Director, Indiana University Center for Bioethics) to co-chair a Task 
Force charged with assessing the 
feasibility of establishing an Adult Stem 
Cell Center at Indiana University. The 
origin of Dean Brater’s request was the 
recent enactment of Indiana Bill, S-268, 
signed into law by Governor Daniels on 
May 20, 2005. The law affects the 
conduct of research involving human 
cloning, embryonic stem cells and adult 
stem cells, and includes a provision 
(Chapter 29.7.2; see Box A) permitting 
the “the board of trustees of Indiana 
University  [to] establish an adult stem 
cell research center”. Further provisions 
contained in Chap 29.7 provide general 
guidance for the establishment of such a 
Center. In a separate appropriation, the 
State provided $50,000 to allow for the 
process of establishing the Center to 
begin.  
While it is assumed that the Legislature’s vision for such a Center may include other 
institutions and regions of Indiana, the IUSM Task Force mandate and focus was limited 
to Indiana University School of Medicine. Our mandate there was to: 
 
• Identify those researchers at IUSM who were active in adult stem cell 
research; 
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• Identify the opportunities and potential benefits (for science and for 
patient care) that the establishment of such a Center at IUSM might 
provide; 
 
• Identify any challenges or impediments to the establishment of such a 
Center. 
 
Moreover, while it is well recognized that no Center can be established without a 
concrete vision for how it will be funded, this report intentionally focuses on the 
scientific potential and opportunity to bring that capacity to fruition, not on the type or 
amount of financial investment needed. Suffice it to say, the investment needs to be 
sufficient to catalyze the kind of scientific potential that exists when groups of this kind 
are organized, and for which IUSM already has experience through the Indiana Genomics 
Initiative (INGEN).  
 
Following consultation with Dean Brater and Executive Associate Dean for Research Ora 
Pescovitz, Drs. Broxmeyer and Meslin agreed that they would constitute a two-person 
Task Force with the expectation that extensive input would be sought from active stem 
cell research at IUSM (and in other IUPUI schools). The Task Force met with 
approximately 40 IUSM-affiliated investigators on eight separate occasions between 
July-September 2005: five separate meetings with individual investigators, two meetings 
with research programs whose work involves adult stem cells, and a half-day retreat on 
September 29 involving approximately 35 participants.  The goals of the retreat were to 
have a focused discussion about the prospects for a Center on the IUSM campus, to 
assess how a Center would affect the current stem cell research at IUSM, and to identify 
unique projects that might serve as illustrative examples for how a Center might 
accomplish what could not be accomplished under current arrangements.  
 
This report is an outgrowth of those encounters, and especially of the retreat. A draft was 
shared with all who participated in the Task Force process. Thus, the information 
presented represents a collaboration of many individuals who are directly involved in the 
field of stem cell research, and as such the report is an integration of many ideas, 
thoughts, and opinions expressed during the task force process. In the end, of course, the 
final conclusions and recommendations are those of the Task Force Co-Chairs. 
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B. Current Stem Cell Research Activity at IUSM 
 
No assessment of the feasibility of establishing a new Center can begin without first 
determining the present status of activity. By “status of activity” we are referring to: 
 
• The quality of faculty working on adult stem cell research, including their 
productivity (peer-reviewed publications and grant support).  
 
• The types of cells being investigated. 
 
• The diseases being targeted for treatment with stem cells. 
 
• Other approaches to assessing research such as biological processes. 
 
• Types of research (from basic to therapeutics). 
 
1. Faculty 
 
The IU School of Medicine has a diverse group of stem cell investigators working in 
several areas and targeting multiple diseases. In rough numbers, there are more than 30 
self-identified adult stem cell researchers affiliated with IUSM, with backgrounds in 
surgery, medicine, genetics, immunology, microbiology, biochemistry, and 
cell/molecular biology. [See Appendix 1] Most prominent is the work currently done that 
studies hematopoietic, cardiovascular, and cancer stem cells.  These researchers have 
enjoyed success in publishing in the peer reviewed literature including more than 450 
publications in the last 6 years. In addition, these investigators have reported success in 
obtaining funding for their work. Over $23 million has been obtained by IUSM 
investigators, with $18.9 million from the NIH, $3 million from private corporations, and 
$1.1 million from philanthropic sources. However, it is important to note that while these 
numbers are impressive, exact figures are not possible to obtain. For example, some 
publications mention the use of stem cells even though the focus of the research was not 
on stem cells per se. Similarly, it is not known what portion of all grant funding is 
devoted exclusively to research on stem cells.  
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2. Adult Stem Cell Types under Investigation as IUSM 
 
The Task Force identified 7 stem cell sources currently under investigation by IUSM 
researchers: Adipose, Epithelial, Endothelial, Hematopoietic, Mesenchymal, Muscle, and 
Neural. [See Table 1] The majority of IUSM-based research involves the study of three 
major cell types: 
 
• Investigators from the IU Cancer Center, the Walther Cancer Center, and the 
programs in hematopoiesis and immunology at the IU Cancer Center are 
investigating hematopoietic, or blood-related cells. Indeed, the largest 
number of investigators, publications, and grant funding is attributed to 
research associated with these cell types. 
 
• A second area of work involves vascular biology and investigates stem cells 
derived from the endothelium of blood vessels, as well as stromal and 
adipose tissues. This is an important area for work since the cell sources have 
potential applicability in multiple disease states. These include, but are not 
limited to, diabetes, nervous system disorders, coronary and vascular disease, 
and cancer. Investigators from the IU Center for Vascular Biology and 
Medicine are using these cell types. 
 
• Finally, an area that currently promises much in the way of potential treatment 
is that of neural stem cells. At IUSM, a small group of investigators from the 
Stark Neuroscience Research Institute are currently working on the basic 
science behind these cells and are performing studies on animal models.  
 
In addition to tissue-focused differentiation, many investigators at IUSM are examining 
the pluripotential differentiation of these cells into more than one cell type. This is an 
attractive area of research in the field of adult stem cell biology, and its development is 
becoming more and more a primary objective for the future. 
 
3. Disease Targets 
 
The Task Force found that there are many potential disease targets now being discussed 
by investigators, however, three in particular have shown promising potential as 
therapeutic foci for adult stem cells: 
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• Cancer and its many variants 
• Coronary and vascular disease 
• Neurodegenerative disorders 
 
Present scientific knowledge indicates that these three disease targets show especially 
promising clinical treatment potential. Further, there is some evidence of effective 
therapeutic use at least in the area of transplantation of bone marrow, peripheral blood, 
and umbilical cord blood stem cells for patients with blood disorders, such as leukemia 
and those with other tumors or genetic disorders whose hematopoietic system is 
compromised by treatment (chemotherapy and radiation).  
 
Cancer is an especially important disease in which the important role of tumor stem cells 
for disease initiation and maintenance has now been recognized. Cancer serves as a target 
for correction of disease through intensive treatment and replacement of normal 
hematopoietic stem cells. It is now believed that it is not the total burden of tumor that 
initiates and maintains cancer, but rather a rarer population of tumor stem cells that 
produce malignant cells. Researchers are ultimately looking to stem cell research as a 
way to discover a means to target these ‘cancer stem cells.’ This differs from existing 
cancer treatment, and in fact may fill a gap left where current therapies actually spare the 
stem-like cells in cancer to the detriment of treatment efficacy. The majority of the 
current success using adult stem cells is in the treatment of cancer, especially through 
transplant procedures. In fact, some of the groundbreaking research in this area was first 
done at IUSM. For example, work that has been done in the Walther Oncology Center 
includes the original research demonstrating that umbilical cord blood collected at the 
birth of a baby contained hematopoietic stem cells that could be used to transplant and 
cure recipients undergoing treatment for malignant and non-malignant disorders. In 
addition, the first proof of principle as to the utility of a cord blood bank that supplied 
cells for the first cord blood transplant was initiated at IUSM. 
 
Cardiovascular disease is the focus for multiple new developments in adult stem cell 
research. There are various causes for coronary and vascular damage, among them poorly 
controlled diabetes mellitus, hypertension, and hypercholesterolemia. The Indiana Center 
for Vascular Biology and Medicine is involved in several new studies to promote 
angiogenesis through use of progenitor and stem cells. Most recently, an FDA-approved 
trial has begun at IUSM in which bone marrow mononuclear progenitor cells are being 
  11
 
used to stimulate angiogenic growth in deteriorating limbs. This trial is the first of its 
kind to be approved in the United States, and will serve as the platform for multiple 
clinical and laboratory investigations, which might, in turn, lead to development of 
intellectual property material. 
 
Neurodegenerative disorders are also among the most prominent targets for adult stem 
cells, with spinal cord injury and certain diseases such as Parkinson’s as a focus of 
research efforts. The Stark Neurosciences Research Institute and other neurology 
researchers in the School of Medicine have worked to differentiate certain adult stem 
cells (neural, stromal) with the goal of practical application for degenerative disease. The 
stem cell approach to these diseases has potential in generating large quantities of brain 
and neuron cells by amplifying or immortalizing the primary neurons in culture. These 
cells could then be used for regeneration, repopulation, and transplantation into a 
damaged central nervous system. Most recently, the Institute has had success in using 
differentiated neural stem cells to help create a trophic environment to increase neuron 
reinnervation in a targeted region. 
 
4. Beyond Cell Type and Disease: Biological Processes 
 
Another important perspective for understanding the potential and future for stem cells is 
that of natural biological processes in response to disease stimuli and the effects of 
temporal change. These processes include: 
 
• Inflammation: unwanted side effects encompassing cell production of 
cytokines and chemokines due to insults to the body 
 
• Recruitment: movement to and retention of cells in the appropriate tissue site 
 
• Proteomics and genomics: study of proteins and genes in cells 
 
• Aging: the decline in physiological and cell function that is associated with 
time 
 
A further process, Regeneration, is among the more exciting areas of investigation on 
the IUPUI campus, especially due to the work of the IU Center for Regenerative Biology 
and Medicine. [See <www.regen.iupui.edu>]. Regeneration involves the production of 
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new cells and tissues. Due to the ongoing difficultly in distinguishing between stem and 
progenitor cell types,  the field of regenerative medicine provides a well respected set of 
research tools and approaches for understanding the prevention and treatment of disease,  
There is much evidence demonstrating that stem cells may act at least in part by a 
paracrine effect, where a trophic environment is created that acts via chemokine/cytokine 
signaling. The most valuable effect of stem cells, from this perspective, is to interact with 
and integrate into the normal functions listed above. As research and knowledge increase, 
this may become even more prominent in understanding the therapeutic applications for 
adult stem cells. 
 
5. Types of Research 
 
Current research at IUSM can be grouped into four categories (See Table 1). 
 
• Basic science: the initial research that studies the character and properties of 
stem cells 
 
• Animal model: the first line for testing the effects of stem cells when 
introduced into living tissue 
 
• Clinical/Translational: the research that studies the effects of stem cells in 
the context of disease in human subjects 
 
• Therapeutics: the study of stem cells used for the purpose of replacement and 
cure in disease states 
 
While the majority of IUSM-based research involves basic science and animal model 
research, this is not dissimilar to the current state of stem cell research in general. In 
addition, some clinical and translational efforts are indeed beginning to take shape and 
we now have an established study for therapeutic applications. Presently, our scientific 
investigators are attempting to collaborate closely with clinicians and clinical 
investigators in identifying specific targets and focusing existing knowledge into 
therapeutic application. Of the 40 self-identified stem cell investigators who are involved 
in the basic science research, all but three work with animal models, while a quarter are 
involved in translational efforts. Only a few are investigating adult stem cells in 
therapeutic application. 
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Table 1 
 
ADULT STEM CELL TISSUE SOURCES 
 Hematopoietic Epithelial/Endothelial, Mesenchymal, Muscle Neural 
Stromal/   
Adipose 
Cancer/ 
Transplant 
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Key: 1 – basic science research 
2 – animal model research 
3 – clinical/translational research 
4 – therapeutics 
 
C. Chang1 
C. Orschell1, 2, 3 
K. Pollok1, 2 
L. Pelus1, 2, 3 
M. Yoder1, 2 
H. Broxmeyer1, 2, 3 
S. Fukuda1  
S. Goebel1, 2 
R. Kapur1, 2 
K. Pollok1, 2 
E. Srour1, 2 
E. Chan1, 2, 3 
R. Chan1, 2, 3 
R. Kapur1, 2 
E. Srour1 (Muscle  stem cells) 
S. Goelbel1, 2 
H. Nakshatri1, 2, 3 
E. Srour1, 2, 3 
F. Zhou/Anthony1, 2 
(Dopamine and serotonin 
stem cells for Parkinsonism  
(motor neurons)) 
 
K. March Lab1, 2 
Coronary 
& 
Vascular 
Disease 
 
E. Srour1, 2, 3 
D 
I 
S 
E 
A 
S 
E 
 
T 
A 
R 
G 
E 
T 
S 
K. March Lab 1, 2, 3 
M. Murphy1, 2, 3 
D. Hou1, 2 
J. Rehman1 
M. Yoder1, 2 
M. Clauss1 
E. Srour1, 2 
K. March Lab 1, 2, 3, 4 
D.Ingram1, 2 
M. Murphy1, 2, 3, 4 
 D. Hou1, 2 
J. Rehman1 
E. Srour1, 2 
K. March Lab 1, 2, 3 
M. Murphy1, 2, 3 
Neuro-
degenerative 
Disorders 
  E. Hashino1  E. Hashino1, 2 
F. Zhou/Anthony1, 2  E. Srour1, 2 
(Adult spinal cord, retinal, Y. Du1  
and sensory stem cells) K. March Lab 1, 2 
Y. Du1, 2 
Regenerative 
 J. Ruiz1, 2 
M. Yoder1, 2 
D. Stocum1, 2 (Derived by 
dedifferentiation) 
E. Chernoff1, 2 
S. Rhodes1, 2 
A. Mescher1, 2 
A. Neff1, 2 
M. King1, 2 
J. Rehman1 
F. Zhou/Anthony1, 2 K. March Lab1, 2 
E. Chernoff1, 2 M. Sturek1, 2 
T. Belecky-Adams1, 2 
 
C. Potential Benefits and Challenges 
 
Box B 
Proposals for Tissue Repositories 
 
Umbilical Cord and Placental Tissue 
The use of somatic stem cells, particularly those stem cells derived 
from umbilical cord and placental tissues, as a therapy to treat human 
disease and aging is rapidly approaching and a need for banked clinical 
grade stem cells of many types, including endothelial and 
mesenchymal, will be the rate-limiting step. The proposed Center 
might not only serve as nationally recognized center for stem cell 
investigation but would be a recognized center for banking umbilical 
cords and placental tissue in order to harvest various cell types found 
within. 
 
A key feature of the Center could be the statewide initiative to SAVE 
OUR STEM CELLS (SOSC).  The focus of would be to develop a 
statewide infrastructure that will permit the collection, distribution, and 
harvesting of umbilical cord and placental tissue for somatic stem cell 
isolation, characterization, testing, cryopreservation, and banking. The 
frozen stem cells are prepared for both research and clinical use to 
permit ongoing advances in the field of adult stem cell research and for 
banking these various cell types in a way that permits statewide and 
national distribution for clinical treatments. 
 
Adipose tissue 
Another feasible banking opportunity might include the establishment 
of a broad-based repository for saving adipose-derived stem cells. This 
development of a novel resource could serve as a bank for IUSM as 
well as outside investigators involved in stromal/adipose stem cell 
research. The collection of these cells would be enabled by the fact that 
they are made available by one of the most commonly practiced 
surgical procedures, and as a result could be accessible for collection, 
typing, and storage to be used in research contexts. 
There are many potential benefits that might become available to Indiana and IUSM with 
the creation of an Adult Stem Cell Center. The Task Force has identified four in 
particular. Among them, 
recruitment of new 
researchers is a necessary 
and attainable possibility. 
Also, the opportunity for 
collaborative work will 
be greatly enhanced. 
Greater collaboration 
will enable increases in 
cross-disciplinary 
studies. Additionally, 
promoting the ability to 
translate basic scientific 
research into tangible 
clinical benefits for 
patients is of high 
importance. A Center 
would contribute to all of 
these goals by creating 
an environment that 
fosters collegiality and 
collaboration among 
adult stem cell investigators. It would also establish a core of activity that could become a 
haven to attract other scientific investigators with interests and expertise in the area of 
adult stem cells.  
 
As a central organization for research activities, the Center would provide an ideal 
situation in which to house various peripheral components of work relating to adult stem 
cells. One such possibility has been suggested involving the storage and use of umbilical 
cord and placental tissues that are usually discarded after birth. Another opportunity 
would involve establishing a broad-based repository for saving adipose-derived cells. 
Normally discarded tissue from already common surgical procedures could be collected, 
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typed and stored. [See Box B] In terms of producing benefits to patients, the Center 
would provide a preexisting apparatus for moving ideas begun at the laboratory level into 
clinical trials, and thus speed the development of treatment. It would allow important 
scientific progress to be developed into treatment trials in Indiana and in so doing, open 
up new opportunities to attract and retain clinician-scientists. 
 
One of the challenges facing a center of this kind is to overcome delays that would inhibit 
the translation of bench to bedside proposals. In the past, a number of basic laboratory 
research findings made at IUSM were not first translated to clinical use here, but rather 
were translated elsewhere. Examples include but are not limited to: (1) the concept and 
research demonstrating that umbilical cord blood collected at the birth of a baby 
contained hematopoietic stem and progenitor cells that could be used to transplant and 
cure recipients undergoing conditioning regimens to treat malignant and non-malignant 
disorders, (2) the concept and research demonstrating that a small molecular weight 
compound, AMD 3100, could be used alone to mobilize hematopoietic stem and 
progenitor cells to the blood, and used in combination with Granulocyte Colony 
Stimulating Factor (G-CSF) to enhance mobilization of these stem and progenitor cells.  
Mobilized stem and progenitor cells are used to transplant patients with malignant and 
non-malignant disorders. Having an ACS Center that encompasses basic pre-clinical and 
clinical research should allow IUSM to quickly facilitate translation of the findings that 
are made here into therapeutic benefit. 
 
A separate challenge for the Center would involve enhancing the development of new 
partnerships with commercial aspects as a funding resource. This potential might be 
present over the longer timeframe, and could include collaboration with existing 
organizations or even the creation of new entities. 
 
D. Conclusions and Recommendations 
 
Conclusions 
 
1. The IU School of Medicine has a well established and diverse base of stem cell 
Investigators working in several areas. There are more than 40 adult stem cell 
researchers affiliated with IUSM, with backgrounds in surgery, medicine, genetics, 
immunology, microbiology, biochemistry, and cell/molecular biology. This suggests that 
the necessary foundation exists at IUSM on which to build a Center.  However, it should 
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be noted that since these researchers self-identified, and because stem cell research is a 
broad category, these numbers are only approximations. [See Appendix 1] 
 
2. Many potential disease targets are being studied by IUSM investigators, involving  
seven different cell sources. Among these, three areas in particular are dominant in 
terms of the weight of current efforts: cancer and its many variants, cardiovascular 
disease, and neurodegenerative disorders. These three areas of prominent research focus 
have shown promising potential as therapeutic foci for adult stem cells, and they form a 
basis from which the research capacity at IUSM can be grown and developed. 
 
3. There is evidence of the capacity to obtain external support for research at IUSM. 
Over $23 million has been obtained by IUSM investigators who self-identified as 
working with adult stem cells, with $18.9 million from the NIH, $3 million from private 
corporations, and $1.1 from philanthropic sources. However, since it is not known what 
percentages of the grants are for stem cell research, these numbers are only 
approximations of funding for stem cell work. 
 
4. There is evidence of positive clinical results from current research efforts and 
emerging clinical trials in other areas. For example: 
 
• Umbilical cord blood, pediatric, and adult blood and bone marrow 
hematopoietic stem cell transplants are now an accepted treatment that has 
helped cure patients with leukemia, other cancers, and non-malignant genetic 
disorders whose hematopoietic systems have been compromised by 
chemotherapy and radiation. While this is an accepted treatment, there 
remains much work to be done in investigating hematopoietic stem cell 
potential and how to most efficiently use these cells 
 
• An FDA approval of a purification protocol involving a stem cell selection 
device based on the work done by IUSM researchers 
 
• An FDA-approved clinical trial is underway in which endothelial progenitor 
cells are being used to stimulate angiogenic growth in deteriorating limbs  
 
• There are also two other related trials that are pending approval 
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5. Many potential scientific benefits are likely to arise from establishing an Adult 
Stem Cell Center, including: 
 
• Providing the opportunity for existing investigators to expand into cross-
disciplinary studies, bringing multiple cell fields and sources into contact; 
 
• Attracting new investigators to IUSM with unique and complementary 
abilities and in so doing;  
 
• Increasing the likelihood of attracting additional external funding from grants, 
contracts, and philanthropy; 
 
• Enhancing synergistic collaboration that promote the exchange and progress 
of ideas; and 
 
• Translating scientific work into clinical trials. This will occur by developing 
an organized structure for translating scientific research so that stem cell 
efforts would be more quickly and easily brought to the patient’s benefit. 
 
Moreover, the scientific benefits may translate into new jobs and have considerable 
intellectual property potential. 
 
6. There are several domestic and international initiatives either underway or 
planned that will have an impact on any IUSM (or state-wide) initiative in this area. 
For example: 
 
• Eight states have passed legislation that provide funding for stem cell 
initiatives, with almost as many others considering similar measures in the 
next year. Three of these are looking exclusively at adult stem cell research, 
while the others are addressing both embryonic and adult stem cells. [See 
Appendix 2 for a more detailed overview]. 
 
• Federal legislation regarding stem cell research is also being considered. In 
May 2005, the US House of Representatives passed HR 810, “to amend the 
Public Health Service Act to provide for human embryonic stem cell 
research.” This bill, if enacted, would expand the number of eligible 
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embryonic stem cell lines for federal funding. Competing legislation is also 
pending, including HR 3144, the “Respect for Life Pluripotent Stem Cell Act 
of 2005,” which focuses on techniques that do not require destruction of an 
embryo. 
 
• In October, 2005, South Korea announced its intention to establish a world 
stem cell hub aimed at making their country the center of a global initiative 
for adult and embryonic stem cell banking and research. The United Kingdom 
and Singapore also have announced broad initiatives. 
 
7. There is growing agreement that advances in stem cell investigation are now 
being made with an eye to cooperative efforts in research, rather than competitive 
ones. However, the rapid pace with which stem cell centers of excellence are being 
considered and then established in the United States and elsewhere leads the task force to 
conclude that time is of the essence if Indiana and IUSM are to attract and retain quality 
researchers and promote leading contributions to knowledge about stem cells. 
 
Recommendations 
 
Recommendation 1. The IUSM should move forward expeditiously with plans to 
develop and establish an Adult Stem Cell Center.  If a Center is not established soon, 
much of the opportunity for Indiana to take a leading role in adult stem cell research may 
be lost. 
 
Recommendation 2. The Center should approach research from the perspective of both 
cell-type and disease target, building from those areas in which IUSM has already 
demonstrated progress: Hematopoiesis, Cardiovascular disease, and Cancer. 
 
Recommendation 3. The Center should promote research at all levels, from basic 
science through therapeutics. However, emphasis should be given to the promotion of 
translational research, and should encourage and enable any application of stem cells for 
patient treatment and cure. 
 
Recommendation 4. The Center should have a multidisciplinary structure, involving 
basic science investigators, clinicians, imaging experts, and geneticists, among others. 
This would allow stem cell research to draw on many areas of science, medicine, and 
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technology to ensure that all the potential therapeutic benefits of adult stem cells are 
realized. Take for example the involvement of radiologists for imaging; other researchers 
capable of following the migration/insertion of labeled stem cells into the targeted organ 
in 3-D rendering, or following dynamic events in 4-D (time); and genomic analysts using 
RNA arrays is a particularly good way to look at global changes in gene expression 
during differentiation. 
 
Recommendation 5. The Center should work to address applications for stem cells 
in research on which IUSM, as yet, has not been able to focus. There are several 
examples of this, such as diabetes mellitus, recognized as a fast-growing and very 
important area of research. Also in this category are certain neurodegenerative disorders, 
among them, spinal cord injury, Parkinsonism, and auditory cell replacement. 
 
Recommendation 6. While describing the potential scientific and clinical merits of such 
a Center are necessary for moving forward with plans for its establishment, other 
logistical and financial issues must be addressed separately. The IUSM should seek 
additional input on the following issues: 
 
• Costs and sources of financing for both start-up and long-term support. 
 
• Logistics, including the space (whether virtual or concrete) in which a Center 
would be located. 
 
• Administrative structure, including whether the Center will function as its 
own department, be housed within an existing department or school, and other 
factors related to reporting relationships. 
 
• Organization of the Center, involving status of involved faculty (full or part 
time), and possible cross-appointments 
 
• Operational focus, both initially and also as expansion and development of the 
Center occur 
 
Recommendation 7. The IUSM should develop a database (or refine an existing one) 
that can identify investigators, publications, and grant support directly related to 
stem cell research. As the Task Force discovered, there are little data to accurately 
  20 
describe which investigators are conducting stem cell research, how productive they are, 
or how much stem-cell specific support they are receiving. More accurate data will be 
valuable in describing the potential for excellence in this area. 
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